These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26194867)

  • 21. Recovery of endothelial function after sirolimus-eluting stent implantation: a pilot study.
    Kitahara H; Fujimoto Y; Ishikawa K; Aoki Y; Iwata Y; Kadohira T; Morino T; Ohkubo K; Sugimoto K; Kobayashi Y
    Angiology; 2013 Apr; 64(3):211-5. PubMed ID: 22523131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
    Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
    Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
    Togni M; Windecker S; Cocchia R; Wenaweser P; Cook S; Billinger M; Meier B; Hess OM
    J Am Coll Cardiol; 2005 Jul; 46(2):231-6. PubMed ID: 16022947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effects of calcium-channel and angiotensin-receptor blockers on endothelial function and inflammatory responses in a porcine drug-eluting stent model.
    Kubota N; Miyauchi K; Kasai T; Iesaki T; Kajimoto K; Sumiyoshi K; Dohi T; Daida H
    Circ J; 2010 Aug; 74(8):1704-10. PubMed ID: 20595778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model.
    Sumida A; Gogas BD; Nagai H; Li J; King SB; Chronos N; Hou D
    Cardiovasc Revasc Med; 2015 Sep; 16(6):351-7. PubMed ID: 26294337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction following drug-eluting stent implantation: a systematic review of the literature.
    Minami Y; Kaneda H; Inoue M; Ikutomi M; Morita T; Nakajima T
    Int J Cardiol; 2013 May; 165(2):222-8. PubMed ID: 22459395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study.
    Rusinaru D; Vrolix M; Verheye S; Chowdhary S; Schoors D; Di Mario C; Desmet W; Donohoe DJ; Ormiston JA; Knape C; Bezerra H; Lansky A; Wijns W;
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1141-50. PubMed ID: 25044635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study.
    Tsuburaya R; Takahashi J; Nakamura A; Nozaki E; Sugi M; Yamamoto Y; Hiramoto T; Horiguchi S; Inoue K; Goto T; Kato A; Shinozaki T; Ishida E; Miyata S; Yasuda S; Shimokawa H;
    Eur Heart J; 2016 Sep; 37(35):2713-21. PubMed ID: 27354043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
    Kimura T; Morimoto T; Natsuaki M; Shiomi H; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Takatsu Y; Nishikawa H; Yamamoto Y; Nakagawa Y; Hayashi Y; Iwabuchi M; Umeda H; Kawai K; Okada H; Kimura K; Simonton CA; Kozuma K;
    Circulation; 2012 Sep; 126(10):1225-36. PubMed ID: 22824435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.
    Shiomi H; Kozuma K; Morimoto T; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Abe M; Suwa S; Muramatsu T; Kobayashi M; Dai K; Nakao K; Uematsu M; Tarutani Y; Fujii K; Simonton CA; Kimura T;
    Circ Cardiovasc Interv; 2014 Jun; 7(3):343-54. PubMed ID: 24803436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial changes of coronary endothelial function and arterial healing after paclitaxel-eluting stent implantation.
    Mitsutake Y; Ueno T; Ikeno F; Yokoyama S; Sasaki K; Nakayoshi T; Itaya N; Chibana H; Sasaki M; Fukumoto Y
    Cardiovasc Interv Ther; 2016 Jan; 31(1):21-8. PubMed ID: 26113198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation.
    Hofma SH; van der Giessen WJ; van Dalen BM; Lemos PA; McFadden EP; Sianos G; Ligthart JM; van Essen D; de Feyter PJ; Serruys PW
    Eur Heart J; 2006 Jan; 27(2):166-70. PubMed ID: 16249221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries.
    Torii S; Nakazawa G; Ijichi T; Yoshikawa A; Ohno Y; Ikari Y
    Cardiovasc Interv Ther; 2018 Jan; 33(1):55-61. PubMed ID: 27822890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
    Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
    J Am Coll Cardiol; 2007 Sep; 50(12):1144-9. PubMed ID: 17868805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of the randomized comparison of everolimus-eluting stents and sirolimus-eluting stent in patients with ST elevation myocardial infarction (RACES-MI trial).
    Di Lorenzo E; Sauro R; Capasso M; Lanni F; Lanzillo T; Carbone G; Manganelli F; Palmieri V; Serino V; Pagliuca MR; Rosato G; Suryapranata H; De Luca G
    Int J Cardiol; 2016 Jan; 202():177-82. PubMed ID: 26397405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.